AMSTERDAM · EST. 2026
Onpeps
PEPTIDE DECISION INTELLIGENCE
Subscribe
← PEPTIDE LIBRARY
METABOLICGRADE DSPECULATIVE / THIN

AOD-9604

hGH fragment 176-191; lipolytic activity (proposed)

A fragment of human growth hormone investigated as a fat-loss agent. Registered obesity trials did not show weight loss superior to placebo, and development as an obesity drug was discontinued.

ALSO KNOWN AS hGH fragment 176-191
REGULATORY STATUS · RESEARCH COMPOUND

Research compound — not approved as a drug. Compounds in this category have not been approved for human use; availability is typically restricted to laboratory research.

§ EVIDENCE BASE
12
PUBLICATIONS
indexed in PubMed
0
REGISTERED TRIALS
listing it as an intervention
0
PHASE 2–4 TRIALS
reached later-stage testing
MECHANISMhGH fragment 176-191; lipolytic activity (proposed)
CATEGORYMetabolic
EVIDENCE GRADED — Speculative / thin
STATUSResearch compound — not approved as a drug
COUNTS RETRIEVED2026-07-23 · re-run the PubMed query
§ RELATED COMPOUNDS
METABOLICA
Semaglutide
GLP-1 receptor agonist
METABOLICA
Tirzepatide
Dual GIP / GLP-1 receptor agonist
METABOLICC
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist
NOT MEDICAL ADVICE

This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.

THE WEEKLY BRIEF

Peptide intelligence, every Monday.

One concise email: the newest research, evidence updates, and quality signals — no hype, no spam.

Onpeps

Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.

EXPLORE
FOLLOW
PEPTIDE INFORMATION YOU CAN VERIFY© 2026 ONPEPS · AMSTERDAM, NETHERLANDS · NOT MEDICAL ADVICE